← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Expression Therapeutics
Tucker, GA
$9,791,313
Total funding
15
Grants
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,791,313 · 15
By mechanism
R44$4,469,084 · 3
R42$2,586,823 · 2
R43$2,535,406 · 8
R41$200,000 · 2
Investigators at Expression Therapeutics
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
High Expression Recombinant Factor VIII$885,011
R42 · FY2011 · HL
Bioengineered factor VIII gene therapy for hemophilia A$826,775
R44 · FY2015 · HL
Bioengineered Recombinant FVIII$809,918
R44 · FY2014 · HL
Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic$752,051
R44 · FY2019 · HL
Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic$747,641
R44 · FY2018 · HL
Ex Vivo Gene Therapy for Hemophilia A$706,219
R42 · FY2009 · HL
Bioengineered Recombinant FVIII$673,613
R44 · FY2015 · HL
Bioengineered factor VIII gene therapy for hemophilia A$659,086
R44 · FY2014 · HL
High Expression Recombinant Factor VIII$575,118
R42 · FY2010 · HL
Ex Vivo Gene Therapy for Hemophilia A$420,475
R42 · FY2010 · HL
Allogeneic cell and gene therapy for neuroendocrine tumors$400,000
R43 · FY2025 · CA
ADEPT-STAR therapy for high risk neuroblastoma$400,000
R43 · FY2023 · CA
Manufacturing Process Development for Bioengineered FVIII$386,432
R43 · FY2013 · HL
Bioengineered factor VIII gene therapy for hemophilia A$378,456
R43 · FY2012 · HL
Development of a novel production platform for complex recombinant biotherapeutic$296,320
R43 · FY2012 · HL
A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer$224,999
R43 · FY2019 · HL
Preclinical Evaluation of Ancestral Coagulation Factor VIII$224,976
R43 · FY2017 · HL
Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette$224,223
R43 · FY2016 · HL
High Expression Recombinant Factor VIII$100,000
R41 · FY2008 · HL
Ex Vivo Gene Therapy of Hemophilia A$100,000
R41 · FY2006 · HL